Intuitive Surgical fundamentals remain strong, says William Blair William Blair believes Intuitive Surgical's fundamentals remain strong following the company's buyback announcement and its call with Dr. Mario Leitao, gynecologic oncologist and co-director of the robotic surgery program at the Memorial Sloan-Kettering Cancer Center. The firm notes that Dr. Leitao does not believe recent reports on safety will change utilization on Intuitive Surgical's da Vinci. William Blair keeps an Outperform rating on the stock.
Intuitive Surgical initiated with an Overweight, $575 target at Barclays Barclays analyst Matthew Taylor started shares of Intuitive Surgical with an Overweight rating and $575 price target. Taylor thinks surgery share will continue to shift to robotic and believes demand for Intuitive's da Vinci among general surgeons is very high. The stock closed yesterday down $4.17 to $492.45.